NVAX:NASDAQ
Novavax Inc
USD 11,22
arrow_downward
-0,88%(-0,100) 1D
USD 11,16
arrow_downward
-0,53% (-0,060)bedtimeAfter hours
Closed: 7 Okt., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
USD 11,01
High
USD 11,75
Low
USD 10,90
Mkt. cap
1,85 mjd
Avg. vol.
6,63 m
Volume
8,38 m
52-wk high
USD 13,38
52-wk low
USD 6,20
EPS
-USD 1,52
Beta
2,44
Shares outstanding
164,95 m
No. of employees
749
Open
USD 11,01
High
USD 11,75
Low
USD 10,90
Mkt. cap
1,85 mjd
Avg. vol.
6,63 m
Volume
8,38 m
52-wk high
USD 13,38
52-wk low
USD 6,20
EPS
-USD 1,52
Beta
2,44
Shares outstanding
164,95 m
No. of employees
749
News stories
From web sources and news partners
Stocktwits
·
15 uur gelede
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
Benzinga
·
15 uur gelede
Transcript: Novavax Q2 2026 Earnings Conference Call
Investing.com
·
17 uur gelede
Novavax and Moderna shares fall after plague concerns ease, Citi comments
Zacks
·
1 dag gelede
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, Verenigde State van Amerika
Sector-
Websitenovavax.com